303 related articles for article (PubMed ID: 29183206)
1. Fibrates in the management of atherogenic dyslipidemia.
Okopień B; Buldak L; Bołdys A
Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
[TBL] [Abstract][Full Text] [Related]
2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
3. Benefits and risks of the treatment with fibrates--a comprehensive summary.
Okopień B; Bułdak Ł; Bołdys A
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
[TBL] [Abstract][Full Text] [Related]
5. The role of fibrate treatment in dyslipidemia: an overview.
Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
[TBL] [Abstract][Full Text] [Related]
6. [Fibrates in the light of large clinical trials].
Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
Pol Merkur Lekarski; 2015 Apr; 38(226):222-7. PubMed ID: 25938391
[TBL] [Abstract][Full Text] [Related]
7. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
8. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
9. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
Bruckert E; Labreuche J; Deplanque D; Touboul PJ; Amarenco P
J Cardiovasc Pharmacol; 2011 Feb; 57(2):267-72. PubMed ID: 21052016
[TBL] [Abstract][Full Text] [Related]
10. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
11. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Moutzouri E; Kei A; Elisaf MS; Milionis HJ
Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
[TBL] [Abstract][Full Text] [Related]
13. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
[TBL] [Abstract][Full Text] [Related]
14. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
Milionis H
Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
[TBL] [Abstract][Full Text] [Related]
15. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
16. CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia.
Mello E Silva A; Aguiar C; Sequeira Duarte J; Couto L; Teixeira Veríssimo M; Marques da Silva P
Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):531-542. PubMed ID: 31447268
[TBL] [Abstract][Full Text] [Related]
17. PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
Ferri N; Corsini A; Sirtori C; Ruscica M
Expert Opin Investig Drugs; 2017 May; 26(5):593-602. PubMed ID: 28343425
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
19. [Gastroenterological aspects of atherosclerosis].
Zvenigorodskaia LA; Samsonova NG; Efremov LI; Cherkashova EA; Lazebnik LB
Eksp Klin Gastroenterol; 2011; (2):31-6. PubMed ID: 21560640
[TBL] [Abstract][Full Text] [Related]
20. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
